SEC 13F Intelligence

Managers / Q4 2020 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$519M
Q4 2020
Positions
24
Filings on Record
31
2019–present window
Filed
Feb 16, 2021
original filing

Summary

Lion Point Capital, LP reported $519M in U.S.-listed holdings across 24 positions for Q4 2020.

Its largest position, TGTX, represents 13.3% of the portfolio.

Compared with Q3 2020, the fund opened 5 new positions and exited 5.

Portfolio Metrics

Turnover
+29.0%
vs prior filed quarter
Top-10 Concentration
+81.2%
share of reported value
Largest Position
+13.3%
Tg Therapeutics
New / Exited
5 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 85.3%Other: 8.8%ETP: 5.9%
  • Common Stock · 85.3% · $443M
  • Other · 8.8% · $46M
  • ETP · 5.9% · $31M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
0LSBURGERFI INTERNATIONAL INCNEW+2.75M2.75M+$38M$38M
INVESCO EXCH TRADED FD TR IINEW+300.0K300.0K+$31M$31M
1T7TRICIDA INCNEW+1.83M1.83M+$13M$13M
BURGERFI INTERNATIONAL INCNEW+2.08M2.08M+$5M$5M
NXTCEURNEXTCURE INCNEW+300.0K300.0K+$3M$3M
AAALCOA CORPSOLD OUT1.70M0$20M$0
ISHARES TRSOLD OUT93.0K0$14M$0
LSCCLATTICE SEMICONDUCTOR CORPSOLD OUT458.2K0$13M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

21 positions
#IssuerClass% PortfolioValueShares
1TGTXTG THERAPEUTICS INChistory →COM13.30%$69M1.33M
2ACHCACADIA HEALTHCARE COMPANY INhistory →COM12.00%$62M1.24M
3CSIQCANADIAN SOLAR INChistory →COM8.69%$45M881.0K
4MARINUS PHARMACEUTICALS INCCOM NEW8.50%$44M3.62M
50LSBURGERFI INTERNATIONAL INChistory →COM7.24%$38M2.75M
6DRRXEURDURECT CORPhistory →COM7.07%$37M17.73M
7ARCONIC CORPORATIONCOM6.71%$35M1.17M
8SWCHFSIERRA WIRELESS INChistory →COM6.03%$31M2.14M
9LIBERTY GLOBAL PLCSHS CL A · SHS CL C5.94%$31M1.27M
10PRSPPERSPECTA INChistory →COM5.80%$30M1.25M
11LUMOS PHARMA INCCOM2.80%$15M407.2K
121T7TRICIDA INChistory →COM2.48%$13M1.83M
13KINIKSA PHARMACEUTICALS LTDCOM CL A1.69%$9M495.7K
14BATLBATTALION OIL CORPhistory →COM1.50%$8M936.0K
15EXTREXTREME NETWORKS INChistory →COM1.08%$6M811.8K
16LOGCUSDLOGICBIO THERAPEUTICS INCCOM0.73%$4M500.0K
17NXTCEURNEXTCURE INCCOM0.63%$3M300.0K
18AGLEUSDAEGLEA BIOTHERAPEUTICS INCCOM0.45%$2M300.0K
19OUTFRONT MEDIA INCCOM0.28%$1M75.0K
20OVVOVINTIV INCCOM0.25%$1M90.1K
21SCOR1EURCOMSCORE INCCOM0.00%$2,0001.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.